Abstract
The emergence of the early COVID-19 epidemic in the United States (U.S.) went largely undetected, due to a lack of adequate testing and mitigation efforts. The city of New Orleans, Louisiana experienced one of the earliest and fastest accelerating outbreaks, coinciding with the annual Mardi Gras festival, which went ahead without precautions. To gain insight into the emergence of SARS-CoV-2 in the U.S. and how large, crowded events may have accelerated early transmission, we sequenced SARS-CoV-2 genomes during the first wave of the COVID-19 epidemic in Louisiana. We show that SARS-CoV-2 in Louisiana initially had limited sequence diversity compared to other U.S. states, and that one successful introduction of SARS-CoV-2 led to almost all of the early SARS-CoV-2 transmission in Louisiana. By analyzing mobility and genomic data, we show that SARS-CoV-2 was already present in New Orleans before Mardi Gras and that the festival dramatically accelerated transmission, eventually leading to secondary localized COVID-19 epidemics throughout the Southern U.S.. Our study provides an understanding of how superspreading during large-scale events played a key role during the early outbreak in the U.S. and can greatly accelerate COVID-19 epidemics on a local and regional scale.
Competing Interest Statement
M.A.S. reports grants from the National Institutes of Health, European Research Council and Wellcome Trust during the conduct of this research and grants and contracts from the Bill & Melinda Gates Foundation, Janssen Research and Development, Private Health Management, IQVIA and the U.S. Department of Veterans Affairs outside the submitted work. S.L.L., R.R. and D.J.N. are employed by BioInfoexperts LLC. R.F.G. reports grants from the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, the Burroughs Wellcome Fund, the Wellcome Trust, the Center for Disease Prevention and Control, and the European & Developing Countries Clinical Trials Partnership. He is the co-founder and Chief Scientific Advisor of Zalgen Labs, a biotechnology company developing countermeasures to emerging viruses, including SARS-CoV-2.
Funding Statement
The research leading to these results has received funding from the National Institutes of Health (grants U19AI135995, 3U19AI135995-03S2, UL1TR002550, U01AI151812, U01AI124302, R01AI153044 and R01HG006139), the European Research Council under the EU Horizon 2020 research and innovation program (grant agreement no. 725422-ReservoirDOCS) and from the EU Horizon 2020 project MOOD (grant agreement no. 874850). The Artic Network receives funding from the Wellcome Trust through project 206298/Z/17/Z. P.L. acknowledges support by the Research Foundation-Flanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, G066215N, G0D5117N, and G0B9317N). S.L.L. acknowledges support by the National Science Foundation Small Business Innovation Research grants 2027424 and 1830867. We also gratefully acknowledge support from NVIDIA Corporation and Advanced Micro Devices, Inc., with the donation of parallel computing resources used for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sample collection, RNA extraction, and viral sequencing was evaluated by the Institutional Review Boards (IRBs) at Tulane University (IRB# 2020-396), Louisiana State University Health System (LSUHS) (IRB# STUDY00001445) and Ochsner Health (IRB# 2019.334). All samples were de-identified before receipt by the study investigators.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are openly available in Github at https://github.com/andersen-lab/paper_2020_new-orleans-hcov-genomics
https://github.com/andersen-lab/paper_2020_new-orleans-hcov-genomics
